Process Engineering Equipment

The average Swiss Process Engineering Equipment company is valued at 4.0 - 6.0× EBITDA on a statutory (tax-based) basis and 5.5 - 8.0× EBITDA in actual deal transactions. The spread between statutory and deal multiples represents a key arbitrage opportunity for informed buyers. The current market trend is stable, with an arbitrage gap rated as medium. Actual valuations depend heavily on recurring revenue share, customer diversification, management depth, and equipment modernity.

Key valuation drivers include: GMP qualification is a documentary moat. Validation packages, material certificates, weld procedure qualifications and an accepted audit history are expensive to reproduce and are why incumbents hold positions on pharmaceutical plants for decades; Recurring revenue from service, spare parts, requalification and validation on an installed base that keeps running independently of new-build demand. Factors that can compress valuations include: The population is thinning fast. NOGA division 28 fell from 2,500 establishments in 2012 to 2,022 in 2022 and 1,968 in STATENT 2024 — 21.3% fewer businesses in twelve years while employment held flat; No official Swiss process engineering series exists. The activity sits inside NOGA division 28 with engineering services counted separately, and the BFS publishes only at division level, so every market size in circulation — including in this report — is an estimate. Deal multiples typically range from 5.5 - 8.0× EBITDA, but actual prices vary significantly based on customer concentration, management quality, revenue predictability, and geographic reach within Switzerland's 26 cantons.

There is no official Swiss process engineering turnover series, and no official count of firms in the niche. The activity sits inside NOGA division 28 — manufacture of machinery and equipment — with engineering services counted separately, and the BFS publishes STATENT only at division level, so every market size in circulation, including the CHF ~11.6B in this report, is an estimate. What is measured is the population. BFS STATENT 2024, published 20 August 2026, records 1,968 establishments in division 28 against 2,022 in 2022 and 2,500 in 2012 — a 21.3% fall in twelve years — while employment held essentially flat at 79,054, up 0.5% since 2022 and down 1.1% since 2012. The "~2,200 firms" carried in the February 2026 edition of this report came from the 2022 release and now overstates the population. On the demand side, Swissmem reports machinery exports down 2.1% in H1 2026 and tech industry capacity utilisation of 81.1% in Q2 2026 against a 2015-2025 long-run average of 85.6%. Process equipment sits at the resilient end of that division because pharmaceutical and food plant investment follows regulatory and product cycles rather than the general capital goods cycle, and because service, spare parts, requalification and validation revenue continues on an installed base that runs regardless.

The succession wave in Swiss process engineering is not a forecast; a large part of it has already happened, and the statistics record it. BFS STATENT 2024, published 20 August 2026, shows 1,968 establishments in NOGA division 28 against 2,500 in 2012 — 21.3% fewer businesses — while employment across the division held essentially flat at 79,054. A fifth of the companies disappeared and the work did not. That is consolidation through ownership transfer, and it tells a current owner two things: there is an active buyer side, and waiting is not free. What a buyer is acquiring in this niche is documentary rather than physical. A GMP-qualified supplier holds validation packages, material certificates, weld procedure qualifications and an audit history that a pharmaceutical customer's quality organisation has already accepted. None of it is patented, all of it is slow and expensive to reproduce, and in practice it lives with the welding coordinator, the validation engineer and the quality lead. If those approvals are not transferred cleanly and the documentation is not demonstrably complete, the acquired business is worth materially less than the diligence assumed — and requalification with the end customer is a multi-year process, not a fiscal-year fix. The trading environment argues for preparation rather than haste. Swissmem machinery exports fell 2.1% in H1 2026 and tech industry capacity utilisation stood at 81.1% against a long-run average of 85.6%, but process equipment sits at the resilient end of that division, buffered by pharmaceutical and food capex cycles and by recurring service, spare parts and requalification revenue on an installed base that runs regardless. Owners should document the qualification file as deliberately as the accounts, name the individuals the approvals depend on, and allow two to three years of overlap. Deal multiples for the sector typically run 5.5 - 8.0× EBITDA.

Four trends define the sector in 2026: (1) A fifth of the establishment base has gone since 2012 — BFS STATENT 2024, published 20 August 2026, records 1,968 establishments in NOGA division 28 — machinery and equipment — against 2,022 in 2022 and 2,500 in 2012. (2) Machinery exports fell 2.1% in H1 2026, but process equipment is at the resilient end — Swissmem's H1 2026 subsector data show machinery exports down 2.1%, with tech industry capacity utilisation at 81.1% in Q2 2026 against a 2015-2025 average of 85.6%. (3) The barrier to entry is documentary, not technical — A GMP-qualified process equipment supplier holds validation packages, material certificates, weld procedure qualifications and an audit history that a pharmaceutical customer's quality organisation has already accepted. (4) The register corrects four entries and confirms a verifiable core — GEA's Swiss company is GEA Suisse AG, registered in Kirchberg (BE), not Pratteln (BL).

The principal acquisition risks are: (1) US tariff escalation through 2025-2026 — 39% in August 2025, capped at 15% in November 2025, Section 232 steel, aluminium and copper duties of 10-50% from April 2026 — raises the cost of stainless steel, Hastelloy and specialty alloys that this niche cannot substitute downward; (2) Customer consolidation. As pharmaceutical and food groups reduce their approved supplier lists, a firm that loses its slot cannot regain it within a fiscal year, because requalification is itself a multi-year process; (3) Franc strength against German, Italian and Chinese plant builders competing for the same projects with lower cost bases. Buyers should conduct thorough due diligence on customer concentration, regulatory compliance, and key-person dependencies. Deal multiples of 5.5 - 8.0× EBITDA may be discounted for firms with elevated risk profiles.

The typical cost breakdown for a Swiss Process Engineering Equipment firm is: Raw Materials (stainless steel, Hastelloy, specialty alloys): 25%, Personnel Costs: 34%, Engineering & Design: 12%, Equipment Depreciation & Tooling: 8%, Quality Assurance & GMP Compliance: 6%, Energy & Utilities: 3%, Other Operating Costs: 3%, Profit Margin (EBITDA): 9%. Indicative split for a Swiss process equipment builder working to GMP standards. Materials dominate and cannot be substituted downward: stainless steel, Hastelloy and specialty alloys carry material certificates that form part of the validation package, so a cheaper grade is not an option even when input costs move. That matters more since the US tariff escalation of 2025-2026 — 39% in August 2025, capped at 15% in November 2025, Section 232 steel, aluminium and copper duties of 10-50% from April 2026. Engineering and design carry a larger share than in general machinery because each plant is configured to a customer process, and quality assurance and GMP compliance are recurring rather than one-off costs. Swissmem reported machinery exports down 2.1% in H1 2026 and tech industry capacity utilisation of 81.1% in Q2 2026 against a long-run average of 85.6% (2015-2025), while NOGA division 28 lost 21.3% of its establishments between 2012 and STATENT 2024 with employment essentially unchanged. These benchmarks are important for buyers assessing operational efficiency and margin improvement potential post-acquisition.

Switzerland's main Process Engineering Equipment clusters are: (1) Basel region (BL) — The pharmaceutical process cluster, and the one where GMP qualification is the entry ticket. (2) Eastern Switzerland (SG) — Food and materials processing at global scale. Bühler AG in Uzwil, with Bühler Holding AG at the same seat, is one of the two Swiss anchors of the sector and sustains a deep local supplier and engineering base across grain, food and advanced materials processing. (3) Zurich and Winterthur (ZH) — Fluid handling, separation and food process technology. Sulzer AG in Winterthur, with Sulzer Management AG alongside, builds pumps and separation and mixing technology for chemical, energy and water applications; Bucher Unipektin AG in Niederweningen builds juice processing, dewatering presses and membrane filtration systems. (4) Mittelland and Fribourg (AG, BE, FR) — Independent specialists rather than group subsidiaries. Ferrum AG in Schafisheim (AG) builds centrifuge systems for chemical, pharmaceutical and sugar processing; GEA Suisse AG is registered in Kirchberg (BE), not Pratteln as earlier editions of this report stated; and Frewitt fabrique de machines S.A. in Granges-Pacco Regional concentration affects valuations, as companies in established clusters benefit from supplier ecosystems, specialized talent pools, and industry networks.